Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Genome & Co. (314130) Stock Price & Analysis

314130 Stock Chart & Stats

₩3,505.00-₩135.00(-3.71%)
At close: 3:30 PM GMT+9
₩3K₩4K₩5K3 Aug18 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
KRW 3,470.00 - KRW 3,830.00
52-Week Range
KRW 2,745.00 - KRW 10,180.00
Previous Close
KRW 3,640.00
Volume
N/A
Average Volume (3M)
491.46K
Market Cap
KRW 188.39B
Enterprise Value
KRW 133.62B
Total Cash (Recent Filing)
N/A
Total Debt (Recent Filing)
N/A
Price to Earnings (P/E)
―
Beta
0.47
Next Earnings
Nov 12, 2026 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

314130 FAQ

What was Genome & Co.’s price range in the past 12 months?
Genome & Co. lowest stock price was ₩2745.00 and its highest was ₩10180.00 in the past 12 months.
What is Genome & Co.’s market cap?
Genome & Co.’s market cap is ₩188.39B.
When is Genome & Co.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Genome & Co.’s earnings last quarter?
Genome & Co. released its earnings results on Aug 14, 2026. The company reported -₩997.077 earnings per share for the quarter.
Is Genome & Co. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Genome & Co. pay dividends?
Genome & Co. does not currently pay dividends.
What is Genome & Co.’s EPS estimate?
Genome & Co.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genome & Co. have?
Genome & Co. has 53,747,673 shares outstanding.
What happened to Genome & Co.’s price movement after its last earnings report?
Genome & Co. reported an EPS of -₩997.077 in its last earnings report. Following the earnings report the stock price went up 3.587%.
Which hedge fund is a major shareholder of Genome & Co.?
Currently, no hedge funds are holding shares in KR:314130
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology